Derek Lowe comments on the news that Pfizer's (now discontinued) inhaled insulin (Exubera) had led to an increased chance of lung cancer in clinical trials. Considering the difficulties and risks of drug development, it's hard to guarantee outcome of clinical trials, especially when they should take into account that disease often happens on the order of years, not months. "The truth, as far as I can see, is that no one can guarantee the safety of a new drug.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.